Safety concerns: Dosing errors can happen easily with self-adjustment, and long-term impacts of microdosing havent been studied
10.3390/plants11182381 18 KasaralaG.TillmannH
Key Takeaways Folks who take one of the popular GLP-1 weight-loss meds might end up with a cancelled endoscopy or colonoscopy New research suggests the drugs slow the transit of food through the stomach and bowel, leading to imperfect bowel prep before the procedures More research needs to be done to determine if recommendations around bowel prep need to be changed TUESDAY, Oct
With the approval, Medicare coverage for Leqembi is expected to begin right away, with the requirement of a patient registry intended to collect further information on the effectiveness of this drug class in Alzheimers
These pathways influence endothelial proliferation, vessel tone, and capillary formation in vascular research systems
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist administered subcutaneously for type 2 diabetes management and chronic weight management